Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors

Clara Lemos, Volker K. Schulze, Benjamin Bader, Clara D. Christ, Hans Briem, Oliver Politz, Florian Prinz, Simon Holton, Tobias Heinrich, Julien Lefranc, Philip Lienau, Arne Scholz, Franz von Nussbaum, Carl Friedrich Nising, Dominik Mumberg, Marcus Bauser, Andrea Hägebarth

Cancer Res (2018) 78 (13_Supplement): 5873.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5873

Published: 01 July 2018

View article

Journal Articles

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Gerhard Siemeister, Anne Mengel, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Amaury E. Fernández-Montalván, Simon Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Marion Hitchcock, Kirstin Meyer, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer

Cancer Res (2017) 77 (13_Supplement): 287.

DOI: https://doi.org/10.1158/1538-7445.AM2017-287

Published: 01 July 2017

View article

Journal Articles

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich T. Luecking, Arne Scholz, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Philip Lienau, Gerhard Siemeister, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Michael Brands

Cancer Res (2017) 77 (13_Supplement): 984.

DOI: https://doi.org/10.1158/1538-7445.AM2017-984

Published: 01 July 2017

View article

Journal Articles

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Ulrich T. Luecking, Julien Lefranc, Antje Wengner, Lars Wortmann, Hans Schick, Hans Briem, Gerhard Siemeister, Philip Lienau, Christoph Schatz, Benjamin Bader, Gesa Deeg, Franz von Nussbaum, Michael Brands, Dominik Mumberg, Karl Ziegelbauer

Cancer Res (2017) 77 (13_Supplement): 983.

DOI: https://doi.org/10.1158/1538-7445.AM2017-983

Published: 01 July 2017

View article

Journal Articles

Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

Marion Hitchcock, Gerhard Siemeister, Hans Briem, Amaury Ernest Fernandez-Montalvan, Simon Holton, Anne Mengel, Ursula Mönning, Michael Brands, Karl Ziegelbauer, Dominik Mumberg, Franz von Nussbaum.

Cancer Res (2016) 76 (14_Supplement): 2718.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2718

Published: 15 July 2016

View article

Journal Articles

ZK-304709, the oral Multitarget Tumor Growth Inhibitor™, acts via inhibition of cell cycle progression and tumor-induced angiogenesis

Gerhard Siemeister, Hans Briem, Thomas Brumby, Rolf Jautelat, Martin Krueger, Ulrich Luecking, Andreas Reichel, Martina Schaefer, Dominik Mumberg, Klaus Bosslet

Cancer Res (2005) 65 (9_Supplement): 1374–1375.

Published: 01 May 2005

View article

Journal Articles

The dual-specific CDK2 / VEGF-RTK inhibitor ZK-CDK potently inhibits proliferation of human tumor cells, induces apoptosis, and inhibits growth of human xenograft tumors

Gerhard Siemeister, Hans Briem, Thomas Brumby, Martin Haberey, Holger Hess-Stumpp, Rolf Jautelat, Martin Krüger, Ulrich Lücking, Andreas Reichel, Martina Schäfer, Klaus Bosslet

Cancer Res (2004) 64 (7_Supplement): 191.

Published: 01 April 2004

View article

NARROW

Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

ZK-304709, the oral Multitarget Tumor Growth Inhibitor™, acts via inhibition of cell cycle progression and tumor-induced angiogenesis

The dual-specific CDK2 / VEGF-RTK inhibitor ZK-CDK potently inhibits proliferation of human tumor cells, induces apoptosis, and inhibits growth of human xenograft tumors

Email alerts

AACR Journals

Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

Abstract 2718: Synthesis and characterization of novel benzylpyrazole-based BUB1 kinase inhibitors with anti-tumor activity

ZK-304709, the oral Multitarget Tumor Growth Inhibitor™, acts via inhibition of cell cycle progression and tumor-induced angiogenesis

The dual-specific CDK2 / VEGF-RTK inhibitor ZK-CDK potently inhibits proliferation of human tumor cells, induces apoptosis, and inhibits growth of human xenograft tumors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only